Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/qtc-prolongation-induced-by-targeted-biotherapies-used-in-clinical-dKHU6TSQVP
References (96)
-
P. Sager, T. Nebout, B. Darpo (2005)
ICH E14: A New Regulatory Guidance on the Clinical Evaluation of QT/QTc Internal Prolongation and Proarrhythmic Potential for Non-antiarrhythmic DrugsDrug information journal : DIJ / Drug Information Association, 39
-
Patrick Chène, Jean Fuchs, Jacqueline Bohn, C. García-echeverría, P. Furet, Doriano Fabbro (2000)
A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines.Journal of molecular biology, 299 1
-
C. Antzelevitch (2005)
Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes.Heart rhythm, 2 2 Suppl
-
G. Rustin, P. Nathan, J. Boxall, L. Saunders, T. Ganesan, G. Shreeves (2005)
A phase Ib trial of combretastatin A- 4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancerJournal of Clinical Oncology, 23
-
M. Carducci, L. Musib, M. Kies, R. Pili, M. Truong, J. Brahmer, Patricia Cole, R. Sullivan, J. Riddle, J. Schmidt, N. Enas, V. Sinha, D. Thornton, R. Herbst (2006)
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 25
-
G. Blobe, L. Obeid, Y. Hannun (1994)
Regulation of protein kinase C and role in cancer biologyCancer and Metastasis Reviews, 13
-
N. Martin, T. Brunner, K. Kiel, T. Delaney, W. Regine, M. Mohiuddin, E. Rosato, D. Haller, J. Stevenson, Deborah Smith, B. Pramanik, J. Tepper, W. Tanaka, B. Morrison, P. Deutsch, Anjali Gupta, R. Muschel, W. Mckenna, E. Bernhard, S. Hahn (2004)
A Phase I Trial of the Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic CancerClinical Cancer Research, 10
-
J. Denekamp (1982)
Endothelial cell proliferation as a novel approach to targeting tumour therapy.British Journal of Cancer, 45
-
Dierk Thomas, Wei Zhang, C. Karle, S. Kathöfer, W. Schöls, W. Kübler, J. Kiehn (1999)
Deletion of Protein Kinase A Phosphorylation Sites in the HERG Potassium Channel Inhibits Activation Shift by Protein Kinase A*The Journal of Biological Chemistry, 274
-
C. Partovian, M. Simons (2004)
Regulation of protein kinase B/Akt activity and Ser473 phosphorylation by protein kinase Cα in endothelial cellsCellular Signalling, 16
-
G. Rustin, S. Galbraith, H. Anderson, M. Stratford, L. Folkes, L. Sena, L. Gumbrell, P. Price (2003)
Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 15
-
M. Cooney, T. Radivoyevitch, A. Dowlati, B. Overmoyer, N. Levitan, Kelly Robertson, Sandra Levine, Kathleen DeCaro, C. Buchter, Anne Taylor, B. Stambler, S. Remick (2004)
Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced CancerClinical Cancer Research, 10
-
R. Guy (2014)
International Conference on Harmonisation -
R. Natale, S. Thongprasert, F. Greco, Michael Thomas, C. Tsai, P. Sunpaweravong, D. Ferry, C. Mulatero, R. Whorf, J. Thompson, F. Barlesi, P. Langmuir, S. Gogov, J. Rowbottom, G. Goss (2011)
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 8
-
E. Strevel, D. Ing, L. Siu (2007)
Molecularly targeted oncology therapeutics and prolongation of the QT interval.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 22
-
H. Ueda, H. Nakajima, Y. Hori, T. Fujita, M. Nishimura, T. Goto, M. Okuhara (1994)
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity.The Journal of antibiotics, 47 3
-
Jiandong Chen, V. Maréchal, Arnold Levine (1993)
Mapping of the p53 and mdm-2 interaction domains.Molecular and cellular biology, 13 7
-
S. Neuteboom, E. Medina, M. Palladino, M. Spear, G. Lloyd, S. Nawrocki (2008)
450 POSTER NPI-2358, a novel tumor vascular disrupting agent potentiates the anti-tumor activity of docetaxel in the non small cell lung cancer model MV522Ejc Supplements, 6
-
Kristan Keyes, Larry Mann, M. Sherman, E. Galbreath, L. Schirtzinger, D. Ballard, Yun-Fei Chen, P. Iversen, B. Teicher (2004)
LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing miceCancer Chemotherapy and Pharmacology, 53
-
AB Rocha, DR Mans, A Regner (2002)
Targeting protein kinase C: new therapeutic opportunities against high-grade gliomas?Oncologist, 7
-
De-yong Zhang, Yan Wang, C. Lau, H. Tse, Gui-Rong Li (2008)
Both EGFR kinase and Src-related tyrosine kinases regulate human ether-à-go-go-related gene potassium channels.Cellular signalling, 20 10
-
H. Ueda, T. Manda, S. Matsumoto, S. Mukumoto, F. Nishigaki, I. Kawamura, K. Shimomura (1994)
FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.The Journal of antibiotics, 47 3
-
D. End, G. Smets, A. Todd, T. Applegate, C. Fuery, P. Angibaud, M. Venet, G. Sanz, H. Poignet, Stacy Skrzat, A. Devine, W. Wouters, C. Bowden (2001)
Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.Cancer research, 61 1
-
J. Tabernero, L. Dirix, P. Schőffski, A. Cervantes, J. Capdevila, J. Baselga, L. Beijsterveldt, H. Winkler, S. Kraljević, S. Zhuang (2009)
Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
W. Shi, D. Siemann (2005)
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.In vivo, 19 6
-
T. Hammett, S. Oliver, P. Ghahramani, S. Kennedy, I. Fisher, E. Gilmore, T. Duvauchelle, R. Smith (2005)
The pharmacodynamic effect on cardiac repolarization of combination single dose ZD6474 and ondansetron in healthy subjectsJournal of Clinical Oncology, 23
-
C. Tam, H. Kantarjian, G. Garcia-Manero, G. Borthakur, S. O'brien, F. Ravandi, Jenny Shan, J. Cortes (2008)
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.Blood, 112 3
-
A. Balendran, Gregor Hare, A. Kieloch, Michayla Williams, D. Alessi (2000)
Further evidence that 3‐phosphoinositide‐dependent protein kinase‐1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoformsFEBS Letters, 484
-
Y. Nishizuka (1992)
Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C.Science, 258 5082
-
R. Boer, O. Arrieta, Chih‐Hsin Yang, M. Gottfried, Valorie Chan, J. Raats, F. Marinis, R. Abratt, J. Wolf, F. Blackhall, P. Langmuir, T. Milenkova, Jessica Read, J. Vansteenkiste (2011)
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 8
-
D. Roden (2004)
Drug-induced prolongation of the QT interval.The New England journal of medicine, 350 10
-
G. Lorenzo, Riccardo Autorino, G. Bruni, G. Cartenì, E. Ricevuto, M. Tudini, C. Ficorella, C. Romano, M. Aieta, A. Giordano, M. Giuliano, A. Gonnella, C. Nunzio, M. Rizzo, V. Montesarchio, M. Ewer, S. Placido (2009)
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.Annals of oncology : official journal of the European Society for Medical Oncology, 20 9
-
J. Bilenker, K. Flaherty, M. Rosen, L. Davis, M. Gallagher, J. Stevenson, Weijing Sun, D. Vaughn, B. Giantonio, R. Zimmer, M. Schnall, P. O'dwyer (2005)
Phase I Trial of Combretastatin A-4 Phosphate with CarboplatinClinical Cancer Research, 11
-
W. Stadler, K. Margolin, S. Ferber, W. McCulloch, John Thompson (2006)
A phase II study of depsipeptide in refractory metastatic renal cell cancer.Clinical genitourinary cancer, 5 1
-
K. Ratnam, J. Low (2007)
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in OncologyClinical Cancer Research, 13
-
P. Marks, R. Rifkind, V. Richon, R. Breslow, Thomas Miller, W. Kelly (2001)
Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 1
-
R. Niesvizky, S. Ely, M. Diliberto, H. Cho, Udi Gelbshtein, D. Jayabalan, S. Aggarwal, J. Gabrilove, R. Pearse, K. Pekle, F. Zafar, Zoe Goldberg, J. Leonard, J. Wright, S. Chen‐Kiang, M. Coleman (2005)
Multicenter Phase II Trial of the Histone Deacetylase Inhibitor Depsipeptide (FK228) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM).Blood, 106
-
W. Haverkamp, G. Breithardt, A. Camm, M. Janse, M. Rosen, C. Antzelevitch, D. Escande, M. Franz, M. Malik, A. Moss, R. Shah (2000)
The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology.Cardiovascular research, 47 2
-
A. Dowlati, Kelly Robertson, M. Cooney, W. Petros, M. Stratford, J. Jesberger, N. Rafie, B. Overmoyer, V. Makkar, B. Stambler, Anne Taylor, John Waas, J. Lewin, K. McCrae, S. Remick (2002)
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.Cancer research, 62 12
-
S. Hahn, E. Bernhard, W. Regine, M. Mohiuddin, D. Haller, J. Stevenson, Deborah Smith, B. Pramanik, J. Tepper, T. Delaney, K. Kiel, B. Morrison, P. Deutsch, R. Muschel, W. Mckenna (2002)
A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 5
-
R. Shah (2006)
Can pharmacogenetics help rescue drugs withdrawn from the market?Pharmacogenomics, 7 6
-
P. Nathan, I. Judson, A. Padhani, A. Harris, C. Carden, J. Smythe, D. Collins, M. Leach, P. Walicke, G. Rustin (2008)
A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumorsJournal of Clinical Oncology, 26
-
S. Ederhy, A. Cohen, G. Dufaitre, H. Izzedine, C. Massard, C. Meuleman, B. Besse, E. Berthelot, F. Boccara, J. Soria (2009)
QT interval prolongation among patients treated with angiogenesis inhibitorsTargeted Oncology, 4
-
M. Shah, P. Binkley, K. Chan, Jim Xiao, D. Arbogast, Minden Collamore, Yasser Farra, D. Young, M. Grever (2006)
Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine TumorsClinical Cancer Research, 12
-
Zhongju Lu, Chia-Yen Wu, Yaping Jiang, L. Ballou, C. Clausen, I. Cohen, R. Lin (2012)
Suppression of Phosphoinositide 3-Kinase Signaling and Alteration of Multiple Ion Currents in Drug-Induced Long QT SyndromeScience Translational Medicine, 4
-
T. Hagiwara, S. Satoh, Y. Kasai, K. Takasuna (2001)
A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia.Japanese journal of pharmacology, 87 3
-
JOURNAL OF HEMATOLOGY & ONCOLOGY REVIEW Open Access Novel targeted therapeutics: inhibitors of MDM2, -
R. Piekarz, A. Frye, J. Wright, S. Steinberg, D. Liewehr, D. Rosing, V. Sachdev, T. Fojo, S. Bates (2006)
Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell LymphomaClinical Cancer Research, 12
-
Hui Wang, Li Nan, Dong Yu, J. Lindsey, S. Agrawal, Ruiwen Zhang (2002)
Anti-Tumor Efficacy of a Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent MechanismsMolecular Medicine, 8
-
M. Jirousek, P. Goekjian (2001)
Protein kinase C inhibitors as novel anticancer drugsExpert Opinion on Investigational Drugs, 10
-
Juliana Denekamp (1991)
The current status of targeting tumour vasculature as a means of cancer therapy: an overview.International journal of radiation biology, 60 1-2
-
Robin Jones, M. Ewer (2006)
Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugsExpert Review of Anticancer Therapy, 6
-
K. Miller, J. Trigo, C. Wheeler, A. Barge, J. Rowbottom, G. Sledge, J. Baselga (2005)
A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast CancerClinical Cancer Research, 11
-
T. Tamura, H. Minami, Y. Yamada, N. Yamamoto, T. Shimoyama, H. Murakami, A. Horiike, Y. Fujisaka, T. Shinkai, M. Tahara, K. Kawada, H. Ebi, Y. Sasaki, Haiyi Jiang, N. Saijo (2006)
A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant TumorsJournal of Thoracic Oncology, 1
-
F. Barros, D. Gómez-Varela, C. Viloria, Teresa Palomero, T. Giraldez, P. Peña (1998)
Modulation of human erg K+ channel gating by activation of a G protein‐coupled receptor and protein kinase CThe Journal of Physiology, 511
-
E Rubin, J Abbruzzese, B Morrison (2000)
Phase I trial of farnesyl protein transferase inhibitor L-778123 on a 14- or 28-day dosing scheduleProc Am Soc Clin Oncol, 19
-
R. Johnstone (2002)
Histone-deacetylase inhibitors: novel drugs for the treatment of cancerNature Reviews Drug Discovery, 1
-
J. Stevenson, M. Rosen, Weijing Sun, M. Gallagher, D. Haller, D. Vaughn, B. Giantonio, R. Zimmer, W. Petros, M. Stratford, D. Chaplin, Scott Young, M. Schnall, P. O'dwyer (2003)
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 23
-
Yiqiang Zhang, Hui-zhen Wang, Jingxiong Wang, Hong Han, S. Nattel, Zhiguo Wang (2003)
Normal function of HERG K+ channels expressed in HEK293 cells requires basal protein kinase B activityFEBS Letters, 534
-
Wesley Zemrak, G. Kenna (2008)
Association of antipsychotic and antidepressant drugs with Q-T interval prolongation.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 65 11
-
M. Davis, Xin Wu, T. Nurkiewicz, J. Kawasaki, P. Gui, M. Hill, E. Wilson (2001)
Regulation of ion channels by protein tyrosine phosphorylation.American journal of physiology. Heart and circulatory physiology, 281 5
-
STC Neuteboom, E Medina, MA Palladino (2008)
NPI-2358, A novel tumor vascular disrupting agent potentiates the anti-tumor activity of docetaxel in the non small cell lung cancer model MV522 [abstract]Eur J Cancer, 6
-
S. Whittaker, W. McCulloch, T. Robak, E. Baran (2006)
International multicenter phase II study of the HDAC inhibitor (HDACi) depsipeptide (FK228) in cutaneous T-cell lymphoma (CTCL): Interim report.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
J. Tabernero, L. Dirix, P. Schöffski, A. Cervantes, J. López-Martín, J. Capdevila, L. Beijsterveldt, S. Platero, B. Hall, Zhilong Yuan, R. Knoblauch, S. Zhuang (2011)
A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid TumorsClinical Cancer Research, 17
-
L. Beerepoot, J. Rademaker-Lakhai, E. Witteveen, S. Radema, C. Viseren-Grul, L. Musib, J. Hal, J. Beijnen, J. Schellens, E. Voest (2006)
Phase I and pharmacokinetic evaluation of enzastaurin combined with gemcitabine and cisplatin in advanced cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 18_suppl
-
V. Sandor, Susan Bakke, R. Robey, Min Kang, M. Blagosklonny, J. Bender, R. Brooks, R. Piekarz, E. Tucker, W. Figg, K. Chan, B. Goldspiel, A. Fojo, S. Balcerzak, S. Bates (2002)
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.Clinical cancer research : an official journal of the American Association for Cancer Research, 8 3
-
L. Beerepoot, S. Radema, E. Witteveen, T. Thomas, C. Wheeler, S. Kempin, E. Voest (2006)
Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 10
-
J. Graff, A. Mcnulty, K. Hanna, B. Konicek, Rebecca Lynch, S. Bailey, Crystal Banks, A. Capen, R. Goode, J. Lewis, Lillian Sams, Karen Huss, R. Campbell, P. Iversen, B. Neubauer, T. Brown, L. Musib, S. Geeganage, D. Thornton (2005)
The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma XenograftsCancer Research, 65
-
C. Britten, E. Rowinsky, S. Soignet, A. Patnaik, S. Yao, P. Deutsch, Yih Lee, R. Lobell, K. Mazina, Heather McCreery, S. Pezzuli, D. Spriggs (2001)
A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies.Clinical cancer research : an official journal of the American Association for Cancer Research, 7 12
-
W. Haverkamp, G. Breithardt, A. Camm, M. Janse, M. Rosen, C. Antzelevitch, D. Escande, M. Franz, M. Malik, A. Moss, R. Shah (2000)
The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology.European heart journal, 21 15
-
QS Ng, D Carnell, J Milner (2005)
Phase Ib trial of combrestastatin A4 phosphate in combination with radiotherapy: initial clinical resultsJ Clin Oncol, 23
-
Etta Livneh, Daniel Fishman (1997)
Linking protein kinase C to cell-cycle control.European journal of biochemistry, 248 1
-
J. Marshall, N. Rizvi, J. Kauh, W. Dahut, M. Figuera, Min Kang, W. Figg, I. Wainer, Christoff Chaissang, Megan Li, M. Hawkins (2002)
A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.Journal of experimental therapeutics & oncology, 2 6
-
A. Rocha, Dennis Mans, Andrea Regner, Gilberto Schwartsmann (2002)
Targeting protein kinase C: new therapeutic opportunities against high-grade malignant gliomas?The oncologist, 7 1
-
(2005)
International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic DrugsFed Regist, 70
-
S. Sathornsumetee, Kaitlyn Vredenburgh, Kathryn Lattimore, J. Rich (2007)
Malignant glioma drug discovery – targeting protein kinasesExpert Opinion on Drug Discovery, 2
-
L. Rosen, R. Kurzrock, E. Jackson, L. Wathen, M. Parson, M. Eschenberg, M. Mulay, M. Purdom, L. Yan, R. Herbst (2005)
Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumorsJournal of Clinical Oncology, 23
-
F Barros, D Gomez-Varela, CG Viloria (1998)
Modulation of human erg K + channel gating by activation of a G protein coupled receptor and protein kinaseC J Physiol, 511
-
C. Parker, R. Molife, V. Karavasilis, A. Reid, S. Patterson, C. Riggs, C. Higano, W. Stadler, W. McCulloch, J. Bono (2007)
Romidepsin (FK228), a histone deacetylase inhibitor: Final results of a phase II study in metastatic hormone refractory prostate cancer (HRPC)Journal of Clinical Oncology, 25
-
M. Kovacs, D. Reece, D. Marcellus, R. Meyer, S. Mathews, R. Dong, E. Eisenhauer (2006)
A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145Investigational New Drugs, 24
-
S. Holden, S. Eckhardt, R. Basser, R. Boer, D. Rischin, Michael Green, M. Rosenthal, C. Wheeler, A. Barge, H. Hurwitz (2005)
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.Annals of oncology : official journal of the European Society for Medical Oncology, 16 8
-
D. Siemann, M. Bibby, G. Dark, A. Dicker, F. Eskens, M. Horsman, D. Marmé, P. LoRusso (2005)
Differentiation and definition of vascular-targeted therapies.Clinical cancer research : an official journal of the American Association for Cancer Research, 11 2 Pt 1
-
M. Robertson, B. Kahl, J. Vose, S. Vos, M. Laughlin, P. Flynn, K. Rowland, J. Cruz, S. Goldberg, L. Musib, C. Darstein, N. Enas, J. Kutok, J. Aster, D. Neuberg, K. Savage, A. LaCasce, D. Thornton, C. Slapak, M. Shipp (2007)
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 13
-
R. Shah, J. Morganroth, D. Shah (2013)
Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)Drug Safety, 36
-
G. Gintant, J. Limberis, J. McDermott, C. Wegner, B. Cox (2001)
The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced ArrhythmogenesisJournal of Cardiovascular Pharmacology, 37
-
T Hagiwara, S Satoh, Y Kasai (2001)
A comparative study of the various fluoroquinolone antibacterial agents on the cardiac action potential in guinea pig right ventricular myocardiumJpn J Pharmacol, 87
-
S. Wells, B. Robinson, R. Gagel, H. Dralle, J. Fagin, M. Santoro, E. Baudin, R. Elisei, B. Jarzab, J. Vasselli, Jessica Read, P. Langmuir, A. Ryan, M. Schlumberger (2012)
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 2
-
T. Chu, M. Rupnick, R. Kerkela, S. Dallabrida, D. Zurakowski, L. Nguyen, Kathleen Woulfe, Elke Pravda, F. Cassiola, J. Desai, S. George, David Harris, Nesreen Ismail, Jey-Hsin Chen, F. Schoen, A. Abbeele, G. Demetri, T. Force, M. Chen, J. Morgan (2007)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 370
-
J. Weissenburger, V. Nesterenko, C. Antzelevitch (2000)
Transmural Heterogeneity of Ventricular Repolarization Under Baseline and Long QT Conditions in the Canine Heart In Vivo: Torsades de Pointes Develops with Halothane but not Pentobarbital AnesthesiaJournal of Cardiovascular Electrophysiology, 11
-
Andreas Gescher (1998)
Analogs of staurosporine: potential anticancer drugs?General pharmacology, 31 5
-
J. Heymach, B. Johnson, D. Prager, E. Csada, J. Roubec, M. Pešek, I. Špásová, C. Belani, I. Bodrogi, S. Gadgeel, S. Kennedy, J. Hou, R. Herbst (2007)
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 27
-
K. Kiura, K. Nakagawa, T. Shinkai, K. Eguchi, Y. Ohe, N. Yamamoto, M. Tsuboi, S. Yokota, T. Seto, Haiyi Jiang, K. Nishio, N. Saijo, M. Fukuoka (2008)
A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung CancerJournal of Thoracic Oncology, 3
-
Y Yuan, YM Liao, TH Chung (2011)
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARPJ Hematol Oncol, 4
-
S. Bates, D. Rosing, T. Fojo, R. Piekarz (2006)
Challenges of Evaluating the Cardiac Effects of Anticancer AgentsClinical Cancer Research, 12
-
C. Wasylyk, R. Salvi, M. Argentini, C. Dureuil, I. Delumeau, J. Abecassis, L. Debussche, B. Wasylyk (1999)
p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53Oncogene, 18
-
D. Siemann, D. Chaplin (2007)
An update on the clinical development of drugs to disable tumor vasculatureExpert Opinion on Drug Discovery, 2
- Publisher
- Springer Journals
- Copyright
- Copyright © 2014 by Springer International Publishing Switzerland
- Subject
- Medicine & Public Health; Oncology; Biomedicine general
- ISSN
- 1776-2596
- eISSN
- 1776-260X
- DOI
- 10.1007/s11523-014-0325-x
- pmid
- 24970120
- Publisher site
- See Article on Publisher Site
Abstract
In anticancer drug development, there has been increasing consideration for the potential of a compound to cause adverse electrocardiographic changes, especially QT interval prolongation, which can be associated with risk of torsades de pointes and sudden death. Irrespective of overt clinical toxicities, QTc assessment can influence decision making during the conduct of clinical studies, including eligibility for protocol therapy, dose delivery or discontinuation, and analyses of optimal dose for subsequent development. Efforts are needed to refine strategies for risk management, avoiding unintended consequences that negatively affect patient access and clinical development of promising new cancer treatments. In this comprehensive review, we will analyze potential effects on QTc prolongations of targeted agents approved by regulatory agencies and under investigation. A thoughtful risk management plan was generated by an organized collaboration between oncologists, cardiologists, and regulatory agencies to support a development program essential for oncology agents with cardiac safety concerns.
Journal
Targeted Oncology – Springer Journals
Published: Jun 27, 2014